Familial coexistence of primary antiphospholipid syndrome and factor VLeiden

Abstract

The antiphospholipid syndrome (APS) is an autoimmune thrombophilic disorder in which thromboembolism and thrombocytopenia occur. The antiphospholipid antibodies in these patients may cause acquired activated protein C resistance, whereas hereditary activated protein C resistance results from a common single point mutation in coagulation factor V (factor VLeiden). In a family of 11 members with 4 normal subjects, autoimmune thrombocytopenia was documented in 6 patients. Three out of these were found to have thrombocytopenia associated with primary APS. In addition, these 3 subjects were also heterozygous for the factor VLeiden. Only in this group of individuals did life threatening thromboembolic complications occur, while other thrombocytopenic family members showed no thrombotic manifestations. Genetic studies revealed no linkage between APS and HLA class II alleles. Taken together, we present a family with autoimmune thrombocytopenia, which is associated with primary APS in at least 50% of thrombocytopenic individuals. The coexistence of both APS and factor VLeiden in thrombocytopenic subjects, led to an increased number of thrombotic events, suggesting a critical role of combined acquired and hereditary activated protein C resistance in the development of thrombosis in this family. Since no association between APS and specific HLA groups was found, other underlying risk factors for the development of APS must be considered.

Keywords

antiphospholipid syndrome factor VLeiden thrombocytopenia thrombosis

Get full access to this article

View all access options for this article.

References

Asherson RA et al. The ‘primary’ antiphospholipid syndrome: major clinical and serological features . Medicine 1989; 68: 366-374 .

Chong BH , Brighton TC , Chesterman CN. Antiphospholipid anti-bodies and platelets . Semin Thrombos Hemostas 1995; 21: 76-84 .

Oosting JD , Derksen RHWM , Bobbink IWG , Hackeng TM , Bouma BN , de Groot PG.

Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?

Blood 1993; 10: 2618-2625 .

Ruiz-Arguelles GJ et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thrombosis and the antiphospholipid syndrome . J Rheumatol 1991; 18: 552-558 .

Chamley LW , McKay EJ , Pattison NS. Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis . Thromb Res 1993; 71: 103-107 .

Roubey RAS . Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other ‘antiphospholipid’ antibodies . Blood 1994; 84: 2854-2867 .

Borrell M , Sala N , de Castellarnau C , Lopez S , Gari M , Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells . Thrombos Haemostas 1992; 68: 268-272 .

Walker ID , Hickman GM , Stevenson C , McCall F. High prevalence of APC resistance in the presence of antiphospholipids . Br J Haematol 1994; 86: 2-2 .

Matthey F , Walshe K , Mackie IJ , Machin SJ. Familial occurrence of the antiphospholipid syndrome . J Clin Pathol 1988; 42: 495-497 .

10.

Mackie IJ , Colaco CB , Machin SJ. Familial lupus anticoagulants . Br J Haematol 1987; 67: 359-363 .

11.

Shimizu K , Katsuta I , Uchikawa T. Familial lupoid thrombocytopenia . Am J Hematol 1993; 44: 9-11 .

12.

Goldstein R , Moulds JM , Smith CD , Sengar DP. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus . J Rheumatol 1996; 23: 1173-1179 .

13.

Sebastiani GD , Galeazzi M , Morozzi G , Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant . Semin Arthritis Rheum 1996; 25: 414-420 .

14.

Vargas-Alarcon GJ , Drenkard C , Andrade F , Melin-Aldana H , Alcocer-Varela J , Alarcon-Segovia D. Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE) . Lupus 1997; 6: 57-62 .

15.

Griffin JH et al. Activated protein C resistance: molecular mechanisms . Thrombos Haemostas 1995; 74: 444-448 .

16.

Bertina RM et al. Mutation in blood coagulation factor V associated with resistance to activated protein C . Nature 1994; 369: 64-67 .

17.

Dahlbäck B. New molecular insights into the genetics of thrombophilia . Thrombos Haemostas 1995; 74: 139-148 .

18.

Brenner B , Zivelin A , Lanir N , Greengard JS , Griffin JH , Seligsohn U. Hereditary thrombophilia as a multigenic disease: increased thrombotic risk due to combined hereditary heterozygous protein C deficiency and activated protein C . Blood 1996; 88: 877-880 .

19.

Mandel H et al. Coexistence of hyperhomocysteinemia and factor VLeiden mutation: impact on expression of thrombosis . N Engl J Med 1996; 334: 763-768 .

20.

Koelman BPC , Reitsma PH , Allaart CF , Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families . Blood 1994; 84: 1031-1035 .

21.

Alarcon-Segovia D , Ruiz-Arguelles GJ , Garces-Eisele J , Ruiz-Arguelles A. Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome . J Rheumatol 1996; 23: 2162-2165 .

22.

Brenner B , Vulfsons SL , Lanir N , Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis . Br J Haematol 1996; 94: 166-167 .

23.

Simantov R , Lo SK , Salmon JE , Sammaritano LR , Silverstein RL. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies . Thromb Res 1996; 84: 361-365 .

24.

Dizon-Townson D , Hutchison C , Silver R , Branch DW. The factor VLeiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome . Thrombos Haemostas 1995; 74: 1029-1031 .

25.

Biousse V et al. Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506?Gln Mutation . J Rheumatol 1995; 22: 1215-1215 .

26.

Davies KA , Ireland H , Athanassiou P , Loizou S , Lane D , Walport MJ. Factor V Leiden mutation and venous thrombosis . Lancet 1995; 345: 132-133 .

27.

Exner T , Papadopoulos G , Koutts J. Use of a simplified dilute Russell viper venom time (dRVVT) confirms heterogeneity among ‘Lupus Anticoagulants’ . Blood Coag Fibrinol 1990; 1: 259-266 .

28.

Bein G , Hackstein H , Klüter H. DNA typing of human platelet antigen systems 1, 2, 3 and 5 in B-lymphoblastoid cell lines of the international histocompatibility workshop . Tissue Antigens 1997; 49: 443-447 .

29.

Harris EN , Gharavi AE , Hughes GRV . Anti-phospholipid antibodies . Clin Rheum Dis 1985; 11: 591-609 .

30.

Harris EN , Asherson RA , Baguley E , Ridley M , Hughes GRV . A standard anti-cardiolipin (aCL) test: usefulness in identification of the anti-phospholipid syndrome . Thromb Haemost 1987; 58: 392-392 .

31.

Cuadrado MJ , Mujic F , Munoz E , Khamashta MA , Hughes GRV . Thrombocytopenia in the antiphospholipid syndrome . Ann Rheumat Dis 1997; 56: 194-197 .

32.

Finazzi G. The Italian registry of antiphospholipid antibodies . Haematologica 1997; 82: 101-105 .

33.

Key NS. Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid syndrome . J Lab Clin Med 1995; 125: 16-17 .

34.

Matsuda J , Gotoh M , Gohchi K , Kawasugi K , Tsukamoto M , Saitoh N. Resistance to activated protein C activity of an anti-b2-glycoprotein I antibody in the presence of b2-glycoprotein I . Br J Haematol 1995; 90: 204-206 .